Jan. 12: The FDA gave an additional indication to Trisenox (arsenic trioxide) in combination with tretinoin for the treatment of adults with newly diagnosed low-risk acute promyelocytic leukemia. The agency first approved the Teva Pharmaceutical Industries Ltd. infusible in 2000. Following induction therapy, dosing is 0.15 mg/kg daily for 25 doses over a period of […]
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.